Cathrine Leonowens

Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects

Jie Zhou, Cathrine Leonowens, Vijay Ivaturi et al. · Journal of Clinical Anesthesia · 2020 · 115 citations · Full text

Medicine, Anesthesiology, Pharmacology +13

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

Danièle Ouellet, Ekaterina Gibiansky, Cathrine Leonowens et al. · The Journal of Clinical Pharmacology · 2014 · 69 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

Anthony W. Tolcher, Razelle Kurzrock, V. Valero et al. · Cancer Chemotherapy and Pharmacology · 2020 · 58 citations · Full text

Medicine, Oncology, Pharmacology +15

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Danièle Ouellet, Nastya Kassir, Joannellyn Chiu et al. · Cancer Chemotherapy and Pharmacology · 2016 · 57 citations

Medicine, Oncology, Pharmacokinetics +17

Concomitant oral and intravenous pharmacokinetics of trametinib, a <scp>MEK</scp> inhibitor, in subjects with solid tumours

Cathrine Leonowens, Carolyn Pendry, John W. Bauman et al. · British Journal of Clinical Pharmacology · 2014 · 46 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13